| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC2823 |
| Trial ID | NCT05091541 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CT120 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma |
| Year | 2021 |
| Country | China |
| Company sponsor | Nanjing IASO Biotherapeutics Co., Ltd |
| Other ID(s) | CT120C001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||